Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
Wenan Qiang, Orlando Antelope, Matthew S. Zabriskie, et al.
Leukemia (2017) Vol. 31, Iss. 12, pp. 2844-2847
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage, et al.
Cancer Cell (2019) Vol. 36, Iss. 4, pp. 431-443.e5
Open Access | Times Cited: 192
New Promise and Opportunities for Allosteric Kinase Inhibitors
Xiaoyun Lu, Jeff B. Smaill, Ke Ding
Angewandte Chemie International Edition (2019) Vol. 59, Iss. 33, pp. 13764-13776
Closed Access | Times Cited: 147
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Paul W. Manley, Louise Barys, Sandra W. Cowan‐Jacob
Leukemia Research (2020) Vol. 98, pp. 106458-106458
Closed Access | Times Cited: 105
Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery
Shaoyong Lu, Yuran Qiu, Duan Ni, et al.
Drug Discovery Today (2019) Vol. 25, Iss. 1, pp. 177-184
Closed Access | Times Cited: 80
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
Mariana Miranda Sampaio, Maria Luísa Cordeiro Santos, Hanna Santos Marques, et al.
World Journal of Clinical Oncology (2021) Vol. 12, Iss. 2, pp. 69-94
Open Access | Times Cited: 57
Asciminib: First Approval
Emma D. Deeks
Drugs (2022) Vol. 82, Iss. 2, pp. 219-226
Closed Access | Times Cited: 50
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
Govinda Poudel, Molly G. Tolland, Timothy P. Hughes, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3300-3300
Open Access | Times Cited: 39
Asciminib in the treatment of chronic myeloid leukemia in chronic phase
Alessandro Nanni Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Future Oncology (2025), pp. 1-17
Closed Access | Times Cited: 1
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment
Péter Batár, Gabriella Mezei, Árpád Illés
Current Oncology (2025) Vol. 32, Iss. 2, pp. 97-97
Open Access | Times Cited: 1
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Rudolf Pisa, Tarun M. Kapoor
Nature Chemical Biology (2020) Vol. 16, Iss. 8, pp. 817-825
Open Access | Times Cited: 60
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
Eun‐Ji Choi
Blood Research (2023) Vol. 58, Iss. S1, pp. S29-S36
Open Access | Times Cited: 19
A biophysical framework for double-drugging kinases
Chansik Kim, Hannes Ludewig, Adelajda Hadzipasic, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 34
Open Access | Times Cited: 19
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Laura N. Eadie, Verity A. Saunders, Susan Branford, et al.
Oncotarget (2018) Vol. 9, Iss. 17, pp. 13423-13437
Open Access | Times Cited: 48
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
Xiaoyun Lu, Jeff B. Smaill, Ke Ding
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 10726-10741
Closed Access | Times Cited: 43
Novel therapeutic approaches in chronic myeloid leukemia
Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
Leukemia Research (2020) Vol. 91, pp. 106337-106337
Closed Access | Times Cited: 40
Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib
Baswanth Oruganti, Erik Lindahl, Jingmei Yang, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 8, pp. 102238-102238
Open Access | Times Cited: 27
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives
Michele Massimino, Stefania Stella, Elena Tirrò, et al.
Anticancer Research (2020) Vol. 40, Iss. 5, pp. 2457-2465
Open Access | Times Cited: 33
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML
Youlu Pan, Shenxin Zeng, Rongrong Hao, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114442-114442
Closed Access | Times Cited: 20
Resistance mutations in CML and how we approach them
Simona Soverini
Hematology (2023) Vol. 2023, Iss. 1, pp. 469-475
Closed Access | Times Cited: 13
The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
H. Jonathan G. Lindström, Ran Friedman
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 28
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
Mingxing Teng, Marlise R. Luskin, Sandra W. Cowan‐Jacob, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7581-7594
Closed Access | Times Cited: 19
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient
Grégoire Cullot, Valérie Lagarde, Jean-Michel Cayuela, et al.
Annals of Hematology (2025)
Open Access
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action
Akriti G Jain, Jorge E. Cortés
Expert Opinion on Pharmacotherapy (2025)
Closed Access
The 5’ fusion partner modulates response to the STAMP inhibitor asciminib inABL-rearranged ALL
Laura N. Eadie, Daniel P. McDougal, Elias Lagonik, et al.
(2025)
Closed Access
Declaration of Bcr-Abl1 independence
Helong Zhao, Michael W. Deininger
Leukemia (2020) Vol. 34, Iss. 11, pp. 2827-2836
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top